Axonyx to present results of drug development trials for Alzheimer's

By Lisa Kerner

Erie, Pa., Jan. 31 - Axonyx Inc. said it will make three presentations of data on its drug development candidate, Phenserine, and one presentation of data on its drug development candidate, Posiphen, at the 9th International Geneva/Springfield Symposium on Advances in Alzheimer Therapy in Geneva, Switzerland, in April.

Axonyx has been developing Phenserine for the treatment of mild to moderate Alzheimer's disease. Posiphen is being developed for the treatment of Alzheimer's progression, according to a company news release.

The first presentation will highlight data from Axonyx's two curtailed phase 3 clinical trials with Phenserine. It will cover a statistically significant improvement of ADAS-cog score over placebo demonstrated by the 15 mg twice daily group at times following 12 weeks of treatment.

The second presentation will report a trend indicating a preservation of brain volumes for patients on Phenserine treatment in a small group of 16 Alzheimer's patients who had brain volumes assessed before and after six months of treatment with Phenserine tartrate.

The third presentation will outline an ongoing clinical positron emission tomography study of Phenserine, which was begun in November 2004.

The fourth presentation will report the reduction of beta-amyloid (1-42) levels in mouse brain following Posiphen treatment. The reduction in mice was shown to be associated with blood levels of Posiphen that were lower than the levels attained in the first phase 1 human Posiphen study.

Axonyx is a New York-based biopharmaceutical company engaged in the acquisition and development of proprietary pharmaceutical compounds for the treatment of central nervous system disorders.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.